key: cord-1014224-kwcjxo4g
authors: Koo, Ellen H.; Eghrari, Allen O.; Dzhaber, Daliya; Shah, Amar; Fout, Elizabeth; Dubovy, Sander; Maestre-Mesa, Jorge; Miller, Darlene
title: Presence of SARS-CoV-2 Viral RNA in Aqueous Humor of Asymptomatic Individuals
date: 2021-05-19
journal: Am J Ophthalmol
DOI: 10.1016/j.ajo.2021.05.008
sha: 4c20830dd6aabb3eaa435486486396ec7b3eab6c
doc_id: 1014224
cord_uid: kwcjxo4g

PURPOSE: : To determine whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is detectable in the aqueous of asymptomatic individuals presenting for ophthalmic surgery. DESIGN: : Prospective cross-sectional study. METHODS: : Setting and Participants, All patients undergoing anterior segment surgery at an Ambulatory Surgical Center (ASC) belonging to a tertiary academic center in South Florida during a 102-day period between June and September 2020 received nasal swab testing for SARS-CoV-2 and underwent a relevant review of symptoms prior to surgery, with negative results required for both in order to proceed with surgery. Main Outcomes and Measures, A small sample of aqueous humor (approximately 0.2cc) was acquired at the beginning of anterior segment surgery in all participants. Aqueous humor was analyzed for SARS-CoV-2 viral ribonucleic acid (RNA) using real-time reverse transcriptase polymerase chain reaction (rRT-PCR). Demographic information was acquired from participants for secondary analyses. RESULTS: : A total of 70 samples were acquired. Of these, 39 were excluded due to insufficient material or inconclusive results. Out of 31 samples that were successfully analyzed, 6 (19.4%) demonstrated detectable SARS-CoV-2 RNA. None of the six individuals (0%) with detectable viral RNA in aqueous humor reported symptoms during the year, compared to 2 of 25 individuals (8%) with negative samples (p=1). Positive samples were distributed throughout the study period, including both the first and the last day of enrollment. CONCLUSION: : The presence of SARS-CoV-2 viral RNA in aqueous despite negative nasal swab testing confirms its presence beyond the blood-ocular barrier in asymptomatic individuals and raises the possibility that the virus may persist in immunoprivileged spaces despite an absence of symptoms.

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with a spectrum of pathological changes. These include anosmia, cough, fever, respiratory distress, as well as death in severe cases. 1 At the time of this writing, approximately 100 million people have been infected and over 2 million have died worldwide. 2 While initial attention to the ocular milieu in patients infected with SARS-CoV-2 was directed to the ocular surface, 3, 4 recent reports have demonstrated evidence of viral ribonucleic acid (RNA) and proteins within the anterior segment, [5] [6] [7] suggesting that SARS-CoV-2 may enter the eye, and viral proteins may remain in the intraocular space after viremia has ended. 5 Elective anterior segment ophthalmic surgery, in particular, cataract surgery, constitute a large proportion of ambulatory surgery performed each year in the United States. While guidelines for hospitals and Ambulatory Surgical Centers (ASC) continue to evolve during the ongoing COVID-19 pandemic, patients undergoing elective cataract surgery and other anterior segment surgery must generally be asymptomatic and/or demonstrate evidence of a negative nasal swab for SARS-CoV-2.

To date, it is unclear whether viral RNA from SARS-CoV-2 can be detected in the aqueous humor of asymptomatic individuals without known history of COVID-19. In this study, we assessed aqueous humor of patients undergoing elective ophthalmic surgery in Florida, a state with a relatively high prevalence of COVID-19 in the United States, for presence of SARS-CoV-2.

This prospective cross-sectional study was approved by the Institutional Research Board of the University of Miami and adheres to the principles of the Declaration of Helsinki. All patients provided informed consent to participate in the study.

Patients undergoing elective anterior segment surgery at an Ambulatory Surgical Center (ASC) belonging to a tertiary academic center in South Florida, by a single surgeon (EK) were invited to participate in the study. All participants required a negative nasal swab testing 24-72 hours before the procedure.

We excluded cases where sufficient sample aqueous humor volume could not be obtained.

Patients were asked about COVID-19 history prior to clinical visits and surgery was deferred if they described a history of COVID-19 or active symptoms. A questionnaire was administered 3-5 days prior to the scheduled surgery date, asking patients if they had been previously tested for SARS-CoV-2 before surgical-related testing and whether they had experienced symptoms suggestive of COVID-19, including cough, fever, shortness of breath and loss of taste and/or smell. If patients answered yes to either question, they were asked for the date of prior COVID-19 testing.

A total of 70 participants contributed samples. For all 70 participants, samples were collected from only one eye from each participant. These were acquired over 8 surgical days during a 102-day period from June 19, 2020 to September 29, 2020, from 6 segment cases. Of these participants, 33 (52.9%) were women and the median age was 72 (range 37 to 93, interquartile range 65 to 77 years old).

Within 24-72 hours prior to surgery, all patients underwent nasal swab testing for SARS-CoV-2 and tested negative. Patients were also contacted within 72 hours of surgery to confirm the absence of symptoms to proceed.

Aqueous humor was drawn at the beginning of cataract surgery. Using a 1cc syringe and a 30G cannula, approximately 0.2cc of aqueous humor was drawn and sent immediately to the laboratory for analysis. Of the 70 samples acquired, 29 had insufficient volume and were unable to be analyzed. Ten samples produced indeterminate results and were excluded from analysis. A total of 31 samples were Interpretation of results and assay performance were in accordance with the manufacturer's instructions and CDC recommendations. Results were reviewed and accepted only after all controls performed as expected

Medians and interquartile ranges were used for descriptive statistics. Fisher exact test and Wilcoxon Rank Sum Test was utilized to compare participants with and without positive samples.

A total of 31 samples were analyzed. Among donors of samples that were analyzed and excluded, respectively, there was no difference in median age (73 vs. 71 years old, p=0.49) or gender (45% vs. 59%, p=0.34) 8 Viral RNA was detected in 6 out of 31 samples analyzed (19.4%). There was no statistically significant difference in median age (72 vs. 75 years old, p=0.73), or association with female gender (2/6, 33% vs. 12/25, 48%, p=0.66) between positive and negative samples, respectively. Positive samples were acquired during 3 of the 8 surgical days, as depicted in Figure 1 .

Of patients with successfully analyzed samples, 0 of 6 positive patients (0%) had previously undergone SARS-CoV-2 testing, compared to 7 of 25 negative patients (28%, p=0.29).

When asked about cough, fever, shortness of breath and loss of taste/smell in the preceding months, 0 of 6 patients who tested positive (0%) confirmed such symptoms compared to 2 of 25 patients who tested negative (8%, p=1.0). A sample of the questionnaire is included as a Supplementary Table.

In this study, asymptomatic individuals presenting for elective ophthalmic surgery without known history or symptoms of COVID-19 provided aqueous samples in which SARS-CoV-2 viral genetic material was detected.

To date, reports of SARS-CoV-2 genetic material or proteins within the anterior chamber have included individuals with a known history of SARS-CoV-2. Nucleocapsid protein antigens of SARS-CoV-2 were found during cataract surgery in the iris and trabecular meshwork of a patient previously infected with COVID-19. 5 In a series of 11 post-mortem corneas from patients who died from COVID-19, six demonstrated evidence of viral RNA, and one aqueous humor sample tested positive. 6 This study is the first to detect SARS-CoV-2 in the aqueous humor of living individuals and demonstrates that it may be present despite an absence of symptoms.

These data also raise the possibility of viral persistence in immunoprivileged spaces. In the case above, 5 viral proteins were present despite timing two months after known infection. The report highlighted the possibility that SARS-CoV-2 proteins may be found inside the eye and persist after the infection has seemingly cleared from circulation. In our positive cases, all tested negative by nasal swab within 72 hours of the aqueous sample, suggesting that the infection they experienced may have occurred in the past. In addition, all 6 patients answered no to previous COVID-19 related symptoms or previous positive tests according to the questionnaire. This is not surprising or conflicting, as COVID-19 infections frequently occur in so-called -asymptomatic‖ patients. 8 Jin et al recently reported a case of a patient who experienced acute graft rejection and later tested positive for SARS-CoV-2 by PCR, 5 days after the onset of ocular symptoms. 9 The corneal endothelium devoid of vasculature and receives its nourishment from the aqueous humor. This suggests that the aqueous humor may play a role in the rejection of the corneal endothelium in certain patients who have been infected with COVID-19. The presence of viral genetic material in aqueous humor as shown in this study, is consistent with this theory.

Considering that millions of cataract surgeries are performed in the world each year, these findings carry potential implications for this elective surgery. Assessment of aerosolization during phacoemulsification in ex vivo models suggest that potential spread through the air is likely negligible 10,11 but may be dependent on incision size. 12 In two previous reports from patients with known history of COVID-19-a case report of an individual with concurrent herpetic stromal keratitis 13 and a post-mortem series of 16 individuals 14did not identify viral RNA in the aqueous humor. Given the limited numbers of samples in those reports, our data do not contradict these findings but rather offer a more complete understanding that SARS-CoV-2 may be present in a low but substantial proportion of people who have experienced COVID-19.

In the setting of an emerging infectious disease, questions arise regarding safety of surgery and prospective studies can be helpful to generate the statistical power necessary to answer such questions. One limitation of this study was the large number of samples that were unable to be analyzed. This reflects the reality of conducting a prospective study in the setting of an emerging infectious disease, in the absence of commercially available assays for testing aqueous humor for SARS-CoV-2. While we must account for the possibility of false positive and false negative results, the data suggest that contamination is an unlikely contributor to the positive results, as they were distributed across surgical dates and tested on separate days.

We chose Florida for its relatively high rate of COVID-19 incidence 15 at the time of the study. Further research is needed to determine the duration of viral persistence in the eye after the initial infection. As we learned from the EVICT 16 and PREVAIL 7 17 studies, the Ebola virus could be found in the aqueous humor in survivors of the disease, months to years following the infection.

Another limitation of this study is that we did not perform antibody testing at the time of surgery. However, given that patients may take approximately 1 to 3 weeks to develop antibodies following exposure to the virus, 18 a negative antibody test would not necessarily rule out a positive aqueous sample.

Increasing evidence points to a long-term, post-COVID syndrome among survivors of COVID-19. Future studies will be needed to identify whether pathological changes include the eye and the extent to which viral persistence may contribute to such findings.

In conclusion, our study found that SARS-CoV-2 viral genetic material can be present in aqueous humor, including in asymptomatic individuals. The length of viral persistence, if present, is unknown and requires further study. 

The purpose of this study was to investigate whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is detectable in the aqueous of asymptomatic individuals presenting for ophthalmic surgery. This prospective study shows that asymptomatic individuals with no known history of COVID-19 and who test negative by nasal swab testing may still harbor SARS-CoV-2 genetic material in the aqueous humor. These findings support concerns regarding viral persistence in immunoprivileged spaces.

A Novel Coronavirus from Patients with Pneumonia in China

Characteristics of Ocular Findings of Patients With Coronavirus Disease

Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease

Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Protein in the Ocular Tissues of a Patient Previously Infected With Coronavirus Disease

Presence of SARS-CoV-2 RNA in the Cornea of Viremic Patients With COVID-19

Prevalence of SARS-CoV-2 in human post-mortem ocular tissues

A systematic review of asymptomatic infections with COVID-19

Acute Corneal Endothelial Graft Rejection With Coinciding COVID-19 Infection

Aerosol generation through phacoemulsification

Aerosol generation from high speed ophthalmic instrumentation and the risk of contamination from SARS COVID19

Reducing visible aerosol generation during phacoemulsification in the era of Covid-19

Negative polymerase chain reaction for SARS-CoV-2 in aqueous sample of patient with confirmed SARS-CoV-2 and recurrence of herpetic stromal keratitis

Occurrence of SARS-CoV-2 in the intraocular milieu

Analysis of the Spread of COVID-19 in the USA with a Spatio-Temporal Multivariate Time Series Model

Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study: Reverse Transcription-Polymerase Chain Reaction and Cataract Surgery Outcomes of Ebola Survivors in Sierra Leone

Efficacy and Safety Outcomes of Cataract Surgery in Survivors of Ebola Virus Disease: 12-Month Results From the PREVAIL VII Study

Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings